1-(tert-butoxycarbonyl)cyclopentanecarboxylic acid | 1196261-09-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(tert-butoxycarbonyl)cyclopentanecarboxylic acid
• 英文别名: 1-[(2-methylpropan-2-yl)oxy-oxomethyl]-1-cyclopentanecarboxylic acid；cyclopentane-1,1-dicarboxylic acid tert-butyl ester；1-[(2-methylpropan-2-yl)oxycarbonyl]cyclopentane-1-carboxylic acid
• CAS: 1196261-09-2
• 化学式: C₁₁H₁₈O₄
• 分子量: 214.262
• InChiKey: WVBLAQSOEXCAPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(tert-butoxycarbonyl)cyclopentanecarboxylic acid 在 N-甲基吗啉 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 t-Butyl 1-(Hydroxymethyl)cyclopentanecarboxylate
  参考文献：
  名称：

  CYCLOPROPYLAMINES AS LSD1 INHIBITORS

  摘要：

  本发明涉及环丙胺衍生物，其为LSD1抑制剂，可用于治疗癌症等疾病。

  公开号：

  US20150225401A1
• 作为产物：
  描述：

  叔丁基甲基马来酸酯 在 lithium hydroxide monohydrate 、 caesium carbonate 、 1-butyl-3-methylimidazolium Tetrafluoroborate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 5.0h， 生成 1-(tert-butoxycarbonyl)cyclopentanecarboxylic acid
  参考文献：
  名称：

  CYCLOPROPYLAMINES AS LSD1 INHIBITORS

  摘要：

  本发明涉及环丙胺衍生物，其为LSD1抑制剂，可用于治疗癌症等疾病。

  公开号：

  US20150225401A1

文献信息

• NOVEL AMINO ACID DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF
  申请人：Fournie-Zaluski Marie-Claude

  公开号：US20110071218A1

  公开（公告）日：2011-03-24

  The disclosure relates to novel compounds of the formula (I) R 1 NH—CH(R 2 )CH 2 —S—S—CH 2 —C(R 3 )(R 4 )—CONH—C(R 5 )(R 6 )—COOR 7 , in which R 1 is a (acyloxy)alkyl carbamate-C(O)—O—C(R 8 )(R 9 )—OC(O)—R 10 group; R 2 is a hydrocarbon chain, a methylene radical substituted by a heterocycle, R 4 is a hydrogen atom and R 3 is a phenyl or benzyl radical, a heteroaryl, a methylene group substituted by a heterocycle or R 3 and R 4 form together a saturated cycle; R 5 and R 6 are hydrogen, a hydrocarbon chain, a phenyl or benzyl radical or R 5 and R 6 form together a saturated cycle; R 7 is hydrogen, a phenyl or benzyl radical, a group of the formula CR 12 (R 13 )C(O)OR 14 or OCR 12 (R 13 )OC(O)R 14 or OCR 12 (R 13 )OC(O)OR 14 . The disclosure also relates to the use of these compounds as a drug, and to a pharmaceutical composition containing said compounds and a pharmaceutically acceptable carrier. The disclosure further relates to the combined use of at least one cannabinoid derivative and/or morphine or one derivative thereof and/or Gaba derivatives for enhancing the analgesic and anti-depressive effect of the compounds of the formula (I).

  该披露涉及到式(I)的新化合物R1NH—CH(R2)CH2—S—S—CH2—C(R3)(R4)—CONH—C(R5)(R6)—COOR7，其中R1是(酰氧基)烷基碳酸酯-C(O)—O—C(R8)(R9)—OC(O)—R10基团；R2是一个碳氢链，一个被杂环取代的亚甲基基团，R4是一个氢原子，R3是一个苯基或苄基基团，一个杂环基团，一个被杂环取代的亚甲基基团或R3和R4一起形成一个饱和环；R5和R6是氢，一个碳氢链，一个苯基或苄基基团，或R5和R6一起形成一个饱和环；R7是氢，一个苯基或苄基基团，一个式CR12(R13)C(O)OR14或OCR12(R13)OC(O)R14或OCR12(R13)OC(O)OR14的基团。该披露还涉及将这些化合物用作药物，以及含有所述化合物和药学上可接受的载体的药物组合物。该披露还涉及至少一种大麻素衍生物和/或吗啡或其衍生物和/或Gaba衍生物的联合使用，以增强式(I)的化合物的镇痛和抗抑郁效果。
• Inhibitors of HCV replication
  申请人：Hudyma W. Thomas

  公开号：US20060046983A1

  公开（公告）日：2006-03-02

  Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

  化合物I的吲哚类化合物已被描述。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。还描述了包含这些化合物的不同形式和组成，以及制备这些化合物的方法。
• PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP3666766A1

  公开（公告）日：2020-06-17

  The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

  本发明提供了一种由下式[I]代表的化合物或其药学上可接受的盐，对 20-HETE 生成酶具有抑制作用。 (上式[I]中，下式[II]所代表的结构： 代表下式组[III]所代表的任何一种结构： R1、R2、R3 和 R4 独立地代表氢原子、氟原子、甲基或类似物、 R5 代表式组 [IV] 所代表的任何一种结构：
• Cyclopropylamines as LSD1 inhibitors
  申请人：Incyte Corporation

  公开号：US10174030B2

  公开（公告）日：2019-01-08

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，它们是治疗癌症等疾病的 LSD1 抑制剂。
• Pyridine compound substituted with azole
  申请人：TAISHO PHARMACEUTICAL CO., LTD.

  公开号：US11365192B2

  公开（公告）日：2022-06-21

  The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

  本发明提供了一种由下式[I]代表的化合物或其药学上可接受的盐，对 20-HETE 生成酶具有抑制作用。 (上式[I]中，下式[II]所代表的结构： 代表下文式组 [III] 所代表的任何一种结构： R1、R2、R3 和 R4 独立地代表氢原子、氟原子、甲基或类似物，R5 代表式组 [IV] 所代表的任何结构：